InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,732.80
(
0.05%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.15
(
-0.08%
)
Bitcoin
61,857.92
(
-1.66%
)
Post# of 129051
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Flr1

Send PM Follow Ignore
Followers 38
Posts 3642
Boards Moderated 0
Alias Born 01/16/2014

Flr1

Re: sicofbs post# 126083

Wednesday, 09/06/2017 7:56:29 AM

Wednesday, September 06, 2017 7:56:29 AM

Post# of 129051
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

http://www2.marketwire.com/mw/frame_mw?attachid=3166660
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up